ImmuCell (NASDAQ:ICCC) Shares Cross Above 200-Day Moving Average – Here’s What Happened

ImmuCell Co. (NASDAQ:ICCC)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.23 and traded as high as $5.17. ImmuCell shares last traded at $5.23, with a volume of 1,384 shares.

ImmuCell Price Performance

The company has a market capitalization of $46.59 million, a PE ratio of -10.46 and a beta of 0.54. The firm has a fifty day simple moving average of $5.09 and a 200 day simple moving average of $4.23. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 3.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mesirow Financial Investment Management Inc. lifted its position in shares of ImmuCell by 100.0% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 12,178 shares during the period. Citadel Advisors LLC bought a new position in ImmuCell in the fourth quarter worth approximately $149,000. Northern Trust Corp lifted its holdings in ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock worth $229,000 after buying an additional 14,982 shares during the period. Geode Capital Management LLC boosted its position in ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock valued at $332,000 after acquiring an additional 7,878 shares in the last quarter. Finally, Dauntless Investment Group LLC purchased a new position in shares of ImmuCell in the 4th quarter valued at $676,000. 13.47% of the stock is currently owned by institutional investors.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.